Bonti Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 10

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $285M

  • Investors
  • 1

Bonti General Information

Description

Developer of a neurotoxin designed for therapeutic and aesthetic indications for patients with unmet needs. The company develops botulinum neurotoxin for the treatment of muscle hyperactivity, the root cause of musculoskeletal pain in both post-surgical and non-surgical settings, enabling patients to have a long-acting, non-opioid local muscle relaxant without the side effects of currently marketed products.

Contact Information

Website
www.bonti.com
Formerly Known As
Endurance Biotech, Endurance Biotech, Inc.
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Corporate Office
  • 4921 Birch Street
  • Suite 120
  • Newport Beach, CA 92660
  • United States
+1 (949) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bonti Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 24-Oct-2018 $285M 000.00 00000 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 23-Jan-2018 000.00 000.00 000.00 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 10-Apr-2017 000.00 000.00 000.00 Completed Clinical Trials - Phase 2
2. Debt - General 01-Dec-2015 $2M $10.9M Completed Startup
1. Early Stage VC (Series A) 28-Aug-2015 $8.9M $8.9M 000.00 Completed Startup
To view Bonti’s complete valuation and funding history, request access »

Bonti Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00 00 00 00 00 00.000
Series B 0,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A 7,451,478 $0.000100 8% $1.2 $1.2 1x $1.2 21.14%
To view Bonti’s complete cap table history, request access »

Bonti Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a neurotoxin designed for therapeutic and aesthetic indications for patients with unmet needs. The company
Drug Discovery
Newport Beach, CA
10 As of 2018
000.00
00000 0000-00-00
000000&0 000.00

0000 0

rehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excep
0000 000000000
Vancouver, Canada
0 As of 0000
000.00
00000000000 000.00

000000

consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolor
0000 000000000
Newark, CA
0 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bonti Competitors (40)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
viDA Therapeutics Venture Capital-Backed Vancouver, Canada 0 000.00 00000000000 000.00
Cellerant Therapeutics Venture Capital-Backed Newark, CA 0 000.00 00000000000 000.00
Genprex Formerly VC-backed Austin, TX 00 00000 00000000 00000
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
Monopar Therapeutics Formerly VC-backed Wilmette, IL 00 000.00 00000000 000.00
You’re viewing 5 of 40 competitors. Get the full list »

Bonti Patents

Bonti Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220306704-A1 Neurotoxins for use in inhibiting cgrp Inactive 03-Apr-2018 000000000
EP-3773906-A1 Neurotoxins for use in inhibiting cgrp Inactive 03-Apr-2018 000000000
US-20190300583-A1 Neurotoxins for use in inhibiting cgrp Inactive 03-Apr-2018 000000000
AU-2019247751-A1 Neurotoxins for use in inhibiting cgrp Inactive 03-Apr-2018 00000000000
CA-3096032-A1 Neurotoxins for use in inhibiting cgrp Pending 03-Apr-2018 A61K38/4893
To view Bonti’s complete patent history, request access »

Bonti Executive Team (8)

Name Title Board Seat Contact Info
Fauad Hasan Co-Founder, President, Chief Executive Officer & Board Member
Aleksandra Avli Chief Executive Officer
You’re viewing 2 of 8 executive team members. Get the full list »

Bonti Board Members (8)

Name Representing Role Since
Fauad Hasan Bonti Co-Founder, President, Chief Executive Officer & Board Member 000 0000
Jacob Chacko MD Self Board Member 000 0000
You’re viewing 2 of 8 board members. Get the full list »

Bonti Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bonti Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Biovision Ventures Venture Capital Minority 000 0000 000000 0
City Hill Ventures Venture Capital Minority 000 0000 000000 0
Colt Ventures Family Office Minority 000 0000 000000 0
Highlight Capital Venture Capital Minority 000 0000 000000 0
Hunt Technology Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Bonti FAQs

  • When was Bonti founded?

    Bonti was founded in 2015.

  • Who is the founder of Bonti?

    Fauad Hasan, Mike Jarpe Ph.D, David Ramsay, Wajdie Ahmad, and Susan Abushakra MD are the founders of Bonti.

  • Who is the CEO of Bonti?

    Fauad Hasan and Aleksandra Avli are the CEOs of Bonti.

  • Where is Bonti headquartered?

    Bonti is headquartered in Newport Beach, CA.

  • What is the size of Bonti?

    Bonti has 10 total employees.

  • What industry is Bonti in?

    Bonti’s primary industry is Drug Discovery.

  • Is Bonti a private or public company?

    Bonti is a Private company.

  • What is the current valuation of Bonti?

    The current valuation of Bonti is 00000.

  • What is Bonti’s current revenue?

    The current revenue for Bonti is 00000.

  • How much funding has Bonti raised over time?

    Bonti has raised $38.1M.

  • Who are Bonti’s investors?

    Biovision Ventures, City Hill Ventures, Colt Ventures, Highlight Capital, and Hunt Technology Ventures are 5 of 8 investors who have invested in Bonti.

  • Who are Bonti’s competitors?

    viDA Therapeutics, Cellerant Therapeutics, Genprex, NexImmune, and Monopar Therapeutics are some of the 40 competitors of Bonti.

  • When was Bonti acquired?

    Bonti was acquired on 24-Oct-2018.

  • Who acquired Bonti?

    Bonti was acquired by Allergan.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »